Rare Disease Industry Conference, President Wei's Dominating Declaration
In January, the Sakura Country is already deep winter.
In a luxurious office at the headquarters of Takeda Pharmaceuticals in Osaka City, Chairman Takeda Kazuhisa stood before the floor-to-ceiling glass window, gazing at the distant nightscape, his brow furrowed in deep thought.
Takeda Pharmaceuticals is the number one pharmaceutical company in Asia and one of the top ten pharmaceutical giants in the world. The matter that can make him fall into deep thought is obviously not simple.
Three years ago, Takeda Pharmaceuticals acquired Shire Company, a Rare Disease pharmaceutical giant in the Bull Country, in a classic small-to-big-fish merger. The acquisition was worth $65 billion, almost twice the combined revenue of the two companies.
This acquisition seemed to give Takeda a boost, causing its value to soar. It not only jumped into the top ten global pharmaceutical companies, but also surpassed Biogen in sales in the Rare Disease sector, becoming the number one in the Rare Disease field. It also resolved the patent cliff crisis and, more importantly, achieved the transformation from chemical drugs to biopharmaceuticals.
At the same time, the acquisition also saddled Takeda with a massive debt of over $30 billion.
From then on, Takeda Pharmaceuticals embarked on the path of paying off its debts.
The company announced a $10 billion divestiture plan for non-core assets and sold 21 non-core assets, including its old headquarters, within two years.
Through a series of seemingly drastic sell-offs, Takeda's debt reduction efforts proceeded steadily and quickly, allowing it to regain its footing, double its profits, and significantly increase its revenue.
Takeda Pharmaceuticals's move to divest mature products is a wise one. It not only reduces debt but also preserves sufficient funds for the research and development of core products, enabling the company to launch several Orphan Drug in the Rare Disease field.
Other multinational giants are also optimistic about this track, with Pfizer, AstraZeneca, Roche and others following closely behind, launching high-value acquisitions of Rare Disease drug companies.
Suddenly, numerous players emerged and fiercely competed in the field of rare drugs.
Meanwhile, China pharmaceutical giant Three Purities also entered the fray with great fanfare, releasing two groundbreaking Rare Disease Gene Drug, especially the SMA gene drug, which caused Novartis and Roche's exorbitantly priced Orphan Drug to suffer repeated defeats and collapse.
Three Purities also announced that it will continue to develop Gene Drug for Rare Disease, and even made a list.
This situation made Takeda Kazuhisa feel uneasy, as if facing a formidable enemy.
It's important to understand that there are over 7,000 Rare Disease, affecting more than 300 million people worldwide. It's a completely untapped blue ocean market, so having a few more pharmaceutical companies enter the market wouldn't be a big problem and wouldn't create much competition.
However, Three Purities Pharmaceutical Company is quite special and different from other pharmaceutical companies.
Unlike most pharmaceutical companies, it did not develop drugs to alleviate Rare Disease, keeping patients on lifelong medication and maximizing profits.
Instead, they took a radical approach, developing Gene Drug right away, which cured patients and completely eradicated the root cause of Rare Disease.
This is utterly devoid of martial ethics and reason!
Most pharmaceutical companies actually have a tacit understanding that they tend to prefer developing drugs for chronic diseases so that patients can take them continuously. This way, patients can contribute profits to the pharmaceutical company for ten, twenty years, or even a lifetime by taking the medication.
This is the kind of drug that pharmaceutical companies love.
One of the most obvious examples is that pharmaceutical companies hate developing antibiotics because once a patient gets sick, they are cured after taking the medication a few times and do not need to take it again unless the illness recurs.
Then pharmaceutical companies will not be able to continuously profit from patients, and therefore will have little incentive to continue developing new drugs.
The same applies to common vaccines; once you get one shot, you don't need to get any more. It's a one-off deal, so it's no wonder pharmaceutical companies are unhappy with it.
But Rare Disease drugs are different. Patients usually develop the disease from childhood, take medication from a young age, and can continue taking it until they die.
If a drug can be developed that not only sells for a high price but also continues to sell indefinitely, it would be the perfect drug in the eyes of pharmaceutical companies.
However, this tacit understanding was immediately broken by the Three Purities.
When Three Purities made its move, it didn't develop drugs to alleviate symptoms and extract long-term profits; instead, it directly cured all the patients.
Not only did they steal market share from other pharmaceutical companies, but they also used a disruptive approach, completely destroying the entire market with a single blow.
How could this not enrage them, make them furious, and at the same time fill them with fear?
As the leading company in Rare Disease, Takeda Pharmaceuticals is bound to face the enormous impact of Three Purities Pharmaceutical and therefore has no choice but to respond.
This is also why Takeda Kazuhisa and pondered.
It wasn't until the sun set and darkness fell that Takeda Kazuhisa came to his senses.
He summoned several company executives to discuss countermeasures.
"I believe you have already seen the series of measures recently taken by Sanqing Pharmaceutical in China. The appeal of Gene Drug to patients is undeniable. Once Gene Drug is introduced, other disease-relieving drugs will completely lose their market share."
"The company currently has four core therapeutic areas: digestive diseases, blood products, oncology, and Rare Disease. We were already struggling in the oncology field against Three Purities and were gradually transforming, and now we are facing off in the Rare Disease field."
"Rare Disease are the area where the company is currently investing the most, and we absolutely cannot give up on them, not even by taking a single step back."
"Currently, the company has launched many innovative drugs for Rare Disease, covering diseases such as Hemophilia A, Fabre Disease, Gaucher Disease, and Hereditary Angioedema. Last year, two of the company's innovative Rare Disease products, Repatha and Fycompa, were successfully included in the China Reimbursement Drug List. This year, the company expects to launch four more innovative Rare Disease drugs in China."
"All of this demonstrates that the China market is extremely important to the company, and the field of Rare Disease is of paramount importance!"
"Although Three Purities hasn't taken any action against our marketed drugs yet, it's only a matter of time. Gentlemen, what measures should we take?"
After finishing his speech in one breath, Takeda Kazuhisa scanned the executives in front of him with lightning speed, awaiting their response.
The scene fell silent.
After a long silence, CEO Weber, a capable subordinate of the Gaul Country, spoke first, calmly and solemnly.
"Chairman, Three Purities is very powerful and its focus is on Gene Therapy. Judging from the two Gene Drug that are about to be launched, they prefer to target high-priced drugs and focus their efforts on incurable diseases. This does not conflict much with us."
"You should know that our Rare Disease drugs have never been too expensive. Last year, Repatha, which was launched in China, brought the annual treatment cost for Fabre Disease down to less than one million yuan."
"We have always understood the China market very well and dare to set low prices, unlike Sanofi, which has always insisted on the global pricing system and refused to lower prices. Every time we negotiate with China's medical insurance, we can offer a very sincere price reduction."
"Even if Three Purities's Gene Drug compete with ours, we still have a significant price advantage. Their Gene Drug are priced at 300,000 RMB, but we can compete with them by setting our prices lower and providing them to patients who cannot afford Gene Drug."
"In fact, multinational pharmaceutical companies' products are generally on the market for a long time, and some products have already basically recovered their costs. In China, with the support of the medical insurance fund, the market size is quite considerable. From a business perspective, the China market is pure profit; you make money on every product sold."
"As long as we lower our prices and offer sincere quotes, we won't have to worry about finding patients. On the contrary, if we refuse to lower our prices and can't find a payer, these products will have zero market share in China."
"To go further, Three Purities currently doesn't have any drugs that compete with us. Could we consider cooperating with them?"
Takeda Kazuhisa's eyes lit up, and he said approvingly, "You're absolutely right, these are very close to my thoughts."
"Which aspect of cooperation are you referring to?"
"Of course, we should maintain cooperation and tackle different Rare Disease separately."
"In fact, there are too many types of Rare Disease. I would suggest that all pharmaceutical companies unite and reach a cooperation agreement to tackle different Rare Disease. This would effectively avoid redundant research and development, greatly save research and development costs, improve research and development efficiency, and is also a good thing for patients."
"Chairman, what do you say?"
Takeda Kazuhisa nodded repeatedly. "That's right, just what I wanted."
"Therefore, we need to hold an industry conference to bring together all pharmaceutical companies and achieve this important goal."
With a serious expression, Takeda Kazuhisa declared righteously, "As the number one pharmaceutical company in Asia and a leader in Rare Disease, we at Takeda Pharmaceuticals naturally have to shoulder this responsibility!"
******
An invitation appeared on Wei Kang's desk. He opened it and was quite surprised.
"The first Rare Disease Industry Conference will be held in Sea City. We sincerely invite Three Purities to participate in this grand event."
This was actually an invitation from Takeda Pharmaceuticals, inviting Three Purities to attend an industry conference for Rare Disease pharmaceutical companies.
It is said that the event invited the world's top 20 pharmaceutical companies to participate, jointly discuss the research and development direction in the field of Rare Disease, exchange the latest achievements from all parties, and explore the latest applications of Gene Therapy.
"That sounds great!" Wei Kang immediately became very interested. "We should invite Tang Que to go with us; he'll definitely like this kind of thing."
He readily agreed and quickly replied to the other party.
A week later, CEOs and heads of Rare Disease departments from major multinational pharmaceutical companies arrived at Sea City Airport, some even on the same flight.
The CEOs and executives all stayed at the Four Seasons Hotel booked by Takeda. Many of them knew each other well, having been colleagues or classmates, so they gathered in advance to exchange information and discuss their respective strategies.
The next morning, they all gathered in the hotel's auditorium, which also housed major media outlets from around the world.
Such global industry conferences always attract a lot of media attention, and recently Rare Disease have been a hot topic in China, which will also interest the general public.
Takeda Kazuhisa in the main seat, delivered his opening remarks, and then explained the purpose of his visit.
"Distinguished corporate representatives and friends from the media, I believe you are all aware of the purpose of this conference, and many of you have already discussed it. So let me get straight to the point."
"As we all know, there are many types of Rare Disease, but at present, pharmaceutical companies are doing their own research and development. Often, they rush to develop drugs for a single disease, resulting in serious duplication of research and development. This has led to the availability of several drugs for some diseases, while there are no drugs available for others."
"This is not beneficial to patients and creates unnecessary competition for pharmaceutical companies. We can make better plans in advance and tackle different Rare Disease separately. This way, we can invest limited resources in the unlimited research and development of Orphan Drug and benefit more patients."
"Recognizing this, Takeda Pharmaceuticals held this industry conference to encourage major pharmaceutical companies to reach an agreement, define their respective research and development scope, avoid vicious competition and duplication of research, thereby improving research and development efficiency, saving costs, and enabling them to produce results as soon as possible and bring usable medicines to patients."
"We have compiled a list of all Rare Disease, the number of patients, and the medications that can currently provide relief. We hope that everyone will take a look at this list, consider it carefully, and make their own choice."
"Of course, if anyone has different opinions, please feel free to raise them..."
Takeda Kazuhisa spoke eloquently and persuasively on stage, presenting his arguments logically and convincingly.
The company representatives in the audience whispered among themselves, exchanging their views.
Wei Kang did not know the purpose of the conference before he came. After listening to it, he thought about it and immediately agreed with it.
As Takeda said, there are simply too many types of Rare Disease. For Three Purities to develop Gene Drug for each one would not only require a huge amount of effort and resources, but would also take a long time and cannot be accomplished overnight.
The best solution would be to unite all pharmaceutical companies worldwide and work together to overcome these diseases.
After all, wasn't the purpose of Three Purities's initial research on Rare Disease to make medicine available to patients?
Now that someone has made the same suggestion, the Three Purities are naturally happy to listen.
However, there is one important factor that Takeda did not mention, and this is precisely what the Three Purities valued highly.
Takeda's throat was parched from speaking on stage. He picked up his water glass, took a sip, glanced around, and saw that everyone was nodding in agreement. He felt a surge of satisfaction and couldn't help but smile.
"If there are no objections, I suggest that everyone try to define their research and development direction from the list. Of course, if you can't decide now, that's fine too. Once you've decided which Rare Disease you want to develop an innovative drug for, just announce it in advance and let your colleagues know."
"In short, the important thing is to reach a tacit understanding..."
Suddenly, someone in the audience raised their hand, interrupting his speech.
Takeda took a closer look and realized that it was the youngest CEO in the room, Wei Kang of Three Purities, and he immediately felt a sense of panic.
He quickly forced a friendly smile and asked, "So you are President Wei Three Purities. May I ask what your opinion is?"
Wei Kang took the microphone from the staff member, his expression turning serious. "I do have a question I'd like to ask."
Seeing that everyone had pricked up their ears and were listening intently.
He slowly began, "My question is about the price. You didn't mention the price in your statement, and I would like to know if there are any agreements or stipulations regarding the price of Rare Disease drugs."
"As we all know, the Three Purities abhor exorbitantly priced drugs. I have a suggestion: I hope that when you develop new drugs, the prices should not be too outrageous, and especially, you should not create any exorbitantly priced drugs."
"It doesn't matter how expensive your drugs are abroad, but it's absolutely unacceptable for them to be sold at too high a price in China. If your drugs are sold at exorbitant prices in China, then Three Purities may be unable to abide by today's agreement."
"After all, we at Three Purities are known as the Sky-high Drug Sniper, and we hope everyone can understand."
These words immediately caused an uproar in the audience.
At that moment, a pharmaceutical company representative angrily spoke out, "Isn't Three Purities being a bit too domineering? You want to control what prices pharmaceutical companies sell at? Aren't you meddling too much?"
Wei Kang smiled slightly, "This is China. I represent all patients in China, so naturally I can manage the prices. And coincidentally, Three Purities also has the ability to manage them."
He looked at the other person, his eyes suddenly sharpening. "If you don't believe in superstitions, you're welcome to try it."
The other party sneered and stopped replying.
The audience below the stage buzzed with discussion, while the media, with expressions of surprise and delight at this "big news," rushed to take photos and write articles, creating a momentary commotion.
Takeda Kazuhisa quickly took over, saying in a deep voice, "Quiet, everyone. Prices can be discussed slowly. Let's not hurt our harmony. Today, we mainly hope that everyone can put aside their prejudices, reach an industry agreement, and promote the research and development of drugs for Rare Disease."
Wei Kang smiled and remained silent. He had already made his strong statement, which he believed was sufficient to represent the stance of the Three Purities.
If any pharmaceutical company dares to sell exorbitantly priced drugs in China again, he wouldn't hesitate to make an example of them and let them experience being targeted.
Although Wei Kang's words caused some setbacks, the conference progressed rapidly.
After all, no one would openly oppose something that seems to benefit everyone.
The major pharmaceutical companies present, including Three Purities, reached an industry agreement, agreeing to select different diseases for research and development to avoid overlap and waste of resources.
Of course, whether or not it can be done is another matter entirely.
The conference concluded successfully, Takeda Kazuhisa felt relieved. Although he didn't know if the agreement was legally binding, taking the first step was enough for him.
At least he could tell what everyone's true intentions were from the attitudes of the major pharmaceutical companies.
Next, he just needs to unite the pharmaceutical companies he can, even if it's just forming a small circle to promote cooperation, which would be considered as achieving part of his goal in this phase.
The rest is up to time and the market to decide.
Facts will prove how correct his proposal was.